Gujarat Kidney IPO Allotment LIVE: Steps to track status on BSE, NSE — What does GMP signal?

• The company’s operations are geographically concentrated in Gujarat, which exposes performance to regional demand conditions, regulatory changes, and competitive intensity within the state.
• A significant portion of revenues is derived from secondary and tertiary care procedures, making earnings sensitive to fluctuations in patient volumes, case mix, and pricing for higher-value treatments.
• While profitability has improved materially in recent periods, the company’s financial track record at the current scale is relatively limited, and sustaining recent performance levels remains dependent on continued execution.
• The business is doctor-dependent, and the ability to attract and retain experienced medical professionals is critical to maintaining service quality, occupancy levels, and specialty-led growth.
• Exposure to government schemes and insurance-led patients, including Ayushman Bharat, may exert pressure on realisations and working capital cycles due to regulated pricing and reimbursement timelines.
• The hospital business is capital-intensive, and any delays or cost overruns in expansion projects or acquisitions could impact returns and cash flows.
• The company operates in a highly regulated environment, and changes in healthcare regulations, clinical standards, or compliance requirements could increase operating costs or restrict certain procedures.

India’s hospital industry is estimated at around ₹8–9 trillion and is expected to grow at a high single- to low double-digit CAGR over the medium term. This growth is supported by rising healthcare expenditure, an ageing population, an increasing incidence of lifestyle and chronic diseases, and higher health insurance penetration.

Demand is increasingly shifting toward secondary and tertiary care, driven by more complex procedures, better realisations, and referral-based patient inflows. There is also strong growth potential in Tier II and Tier III cities due to the underpenetration of quality healthcare infrastructure and limited public hospital capacity.

Government initiatives such as Ayushman Bharat, a focus on medical infrastructure development, and favourable healthcare policies continue to support the expansion of private hospitals.

Gujarat Kidney and Super Speciality Limited operates as a regional, mid-sized secondary and tertiary care hospital network, positioned between primary care providers and large national chains. The company caters to underserved markets with a focus on specialised treatments and scalable operations.

The company has demonstrated strong operational scale-up, with revenue from operations rising from ₹85.8 crore in FY23 to ₹120.0 crore in FY25, driven by an expansion in bed capacity and stable utilisation.

Profitability improved significantly, with PAT increasing from ₹1.7 crore in FY24 to ₹9.5 crore in FY25, supported by operating leverage and better cost efficiencies.

EBITDA stood at ₹16.6 crore in FY25, reflecting healthy operating margins for a secondary and tertiary care hospital network.

As of June 30, 2025, the hospitals offer a wide range of specialties, including general medicine, general and minimally invasive surgery, orthopaedics, trauma care, joint replacement, obstetrics and gynaecology, respiratory care, cardiology (non-interventional), diabetology, and anaesthesiology.

The company currently operates seven multi-speciality hospitals along with four in-hospital pharmacies. It has a total bed capacity of 490 beds, of which around 340 beds are operational.

Gujarat Kidney and Super Speciality Ltd. is a Gujarat-based healthcare group focused on kidney care and multi-speciality services. The company operates around seven mid-sized hospitals and in-house pharmacies, with roughly 490 beds (about 340 operational) across cities like Vadodara, Godhra, Bharuch, Borsad, and Anand. It offers integrated secondary and tertiary care in nephrology, urology, orthopaedics, cardiology, joint replacement, obstetrics, critical care, diagnostics, and pharmacy at affordable prices for semi-urban and urban patients.

IPO Open Date: Monday, December 22, 2025

IPO Close Date: Wednesday, December 24, 2025

Tentative Allotment: Friday, December 26, 2025

Initiation of Refunds: Monday, December 29, 2025

Credit of Shares to Demat: Monday, December 29, 2025

Tentative Listing Date: Tuesday, December 30, 2025

• Proposed Acquisition of Parekhs Hospital, Ahmedabad – ₹77 crore

Funds will be used to acquire Parekhs Hospital in Ahmedabad, expanding the company’s healthcare footprint.

• Part-payment for Ashwini Medical Centre – ₹12.4 crore

A portion of the proceeds will be allocated toward the part-payment of the purchase consideration for Ashwini Medical Centre.

• Acquisition of Additional Stake in Harmony Medicare – ₹10.78 crore

Funds will be used to acquire additional shareholding in Harmony Medicare Private Limited, increasing the company’s stake.

• Capital Expenditure for New Hospital in Vadodara – ₹30.1 crore

Proceeds will be utilised to set up a new hospital in Vadodara, expanding the company’s healthcare services.

• Robotics Equipment for Vadodara Hospital – ₹6.8 crore

The company plans to purchase robotics equipment for the Gujarat Kidney & Super Specialty Hospital in Vadodara.

• Repayment of Secured Borrowings – ₹1.2 crore

A portion of the proceeds will be used to repay certain secured borrowings, strengthening the company’s financial position.

Gujarat Kidney and Super Speciality IPO received 5.21 times subscription on the final day of share sale. The IPO got bids for 6,89,69,088 shares against 1,32,26,880 shares on offer, as per NSE data.

The category for Retail Individual Investors (RIIs) attracted 19.04 times subscription, while the quota for non-institutional investors received 5.73 times subscription. The portion meant for Qualified Institutional Buyers (QIBs) received 1.06 times subscription.

1. Head to MUFG Intime page using this link: https://in.mpms.mufg.com/Initial_Offer/public-issues.html

2. Under the company name, select Gujarat Kidney

3. Enter any of the following details: PAN App. No, DP/Client ID or Account No./IFSC

4. Hit Submit

1. Head to the NSE IPO allotment page using this link: https://www.nseindia.com/invest/check-trades-bids-verify-ipo-bids

2. Select Equity & SME IPO bid details

3. From the dropdown, select the symbol: GKSL

4. Enter your PAN Number and your Application Number

5. Hit Submit

1. Head to the BSE website using this link: https://www.bseindia.com/investors/appli_check.aspx

2. Select issue type as 'equity'

3. From the issue name dropdown, pick Gujarat Kidney

4. Enter application number or PAN number

5. Select I am not a robot

6. Hit search

Gujarat Kidney IPO GMP today is nil. This means that shares are trading at par with the issue price, and listing will likely be flat -- neither a discount nor a premium.

The listing date for the Gujarat Kidney IPO is December 30.

Gujarat Kidney IPO closed for bidding on Wednesday, witnessing a decent demand for its maiden share sale. Investors are now looking ahead to the Gujarat Kidney IPO allotment. Gujarat Kidney IPO allotment date is today, December 26.

Investors can track Gujarat Kidney IPO allotment easily online on the BSE or the NSE, and even by visiting the website of the registrar.